Preview: Ultragenyx Pharmaceutical's Earnings
Portfolio Pulse from Benzinga Insights
Ultragenyx Pharmaceutical (NASDAQ:RARE) is scheduled to release its quarterly earnings report on February 15, 2024, with an estimated EPS of $-1.62. Analysts and investors will be closely watching for not only an earnings beat but also positive guidance for future growth. The company's past earnings performance shows a mix of misses and beats, with corresponding stock price movements. Shares have been trading at $43.98 as of February 13, showing a 2.78% increase over the last 52 weeks.

February 14, 2024 | 4:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Ultragenyx Pharmaceutical is expected to report an EPS of $-1.62 for the upcoming quarter. Historical data shows mixed reactions to past earnings, with the stock price fluctuating accordingly. Shares have increased by 2.78% over the last year.
Given Ultragenyx's mixed past earnings performance and the current positive year-to-date stock performance, the short-term impact of the upcoming earnings report is uncertain. The stock could move in either direction based on whether the company beats the EPS estimate and provides positive future guidance. Historical data shows that the company's stock price can react positively even when missing EPS estimates, suggesting investor focus may be more on guidance than on meeting or beating estimates.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100